Cancer Cancer
Conditions
Interventions
Gemcitabine
Bleomycin plus Vincristine
Sponsors
AMPATH Oncology Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically confirmed Kaposi's sarcoma Documented HIV positive state Documented CD4 cell count Signed informed consent form Stage T0 should have taken ARVs for at least 8 weeks Age over 18 years Adequate hematologic function i.e neutrophil count more than 1000/microliter of bllod,plateles more than 75000 and HB more tha 10grams Creatinine level less tha 200mocrograms per ml of blood ECOG score less than 2 Negative pregnancy test with dual contraception for women of reproductive age
Exclusion criteria
Exclusion criteria: Previous treatment with chemotherapy or radiotherapy Unmeasurable KS lesions Concurrent febrile illneses Concurrent malignancy Allergic reaction to any of the study drugs Breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate, both complete and partial in both study arms. Response will be made by reduction ins-size through bi-directional measurement.;Descrition of drug-associated adverse effects in both arms;Patient quality of life in both arms | — |
Countries
Kenya
Contacts
Public ContactJob Kisuya
Research Manager
Outcome results
None listed